Quaternary ammonium anti-cholinergic muscarinic receptor antagonists
A method administers quaternary ammonium anti-cholinergic muscarinic receptor antagonists in combination with acetyl-cholinesterase inhibitors to treat either cognitive impairment or acute delirium. This therapy results in a modification of a cognitive disorder or disease, namely a slow down in the disease progression. In one preferred embodiment, the disease is dementia with Lewy Bodies. New formulations for quaternary ammonium anti-cholinergic muscarinic receptor antagonists are also disclosed.
1. A quaternary ammonium anti-cholinergic muscarinic receptor antagonist comprising a salt comprising a lipophilic anion as an anionic component of the salt and a cation selected from the group consisting of glycopyrrolate and trospium.
2. The quaternary ammonium anti-cholinergic muscarinic receptor antagonist of claim 1 , wherein the lipophilic anion comprises a fatty acid comprising at least eight carbon atoms.
3. The quaternary ammonium anti-cholinergic muscarinic receptor antagonist of claim 2 , wherein the fatty acid is selected from the group consisting of: stearic acid, palmitic acid, oleic acid, erucic acid, linoleic acid, arachidonic acid, and myristic acid.